Welcome to our dedicated page for Hamilton Lane news (Ticker: HLNE), a resource for investors and traders seeking the latest updates and insights on Hamilton Lane stock.
Hamilton Lane Incorporated reports developments tied to its private markets investment platform, which provides investment solutions for institutional and private wealth clients. Company news commonly covers earnings releases, private credit and private infrastructure products, interval fund structures, capital-structure actions, and funds managed by Hamilton Lane participating in private equity, renewable infrastructure, and continuation-vehicle transactions.
Updates also include senior promotions across investment and client functions and product-access initiatives such as daily NAV pricing, quarterly repurchase features, and tokenized access where offered through specific fund structures.
Hamilton Lane (Nasdaq: HLNE) reported first-quarter fiscal 2027 results for the period ended June 30, 2026, and directed investors to a detailed presentation on its Shareholders website.
The company declared a quarterly dividend of $0.60 per Class A share, implying a target full-year dividend of $2.40, an 11% increase over the prior fiscal year. As of June 30, 2026, Hamilton Lane reported $1.1 trillion in assets under management and supervision, including $146.3 billion in discretionary and $914.1 billion in non-discretionary assets.
Hamilton Lane (Nasdaq: HLNE) served as the sole lead investor and only source of new outside capital in a single-asset continuation vehicle for Savant Capital Holdings, sponsored by Cynosure Partners. The continuation vehicle closed with approximately $270 million in total commitments, providing a liquidity option to Cynosure’s original limited partners roughly ten years after its initial Savant investment.
According to Hamilton Lane, Savant is a large independent fee-only RIA with over $57 billion in assets under management, serving more than 25,000 clients across 70 offices/b. Cynosure remains an active minority investor and Board member alongside Kelso, while Savant employees continue as the largest shareholder group.
Hamilton Lane (Nasdaq: HLNE) announced that its Board of Directors elected Michael Schmertzler as a new independent director, effective July 22, 2026. His appointment brings the Board to five independent directors, serving alongside three executive directors.
Schmertzler has extensive investment, corporate finance and governance experience, including academic roles at Yale University and leadership positions at multiple companies such as PTC Therapeutics, Berryville Holdings, Dispel, SHY Therapeutics and AgNovos. Earlier in his career, he held senior roles at Credit Suisse First Boston Equity Partners and Morgan Stanley.
Hamilton Lane (Nasdaq: HLNE) will release first quarter fiscal 2027 results for the period ended June 30, 2026, before the market opens on August 4, 2026. An earnings release and detailed presentation will be available on the company’s shareholder website.
Hamilton Lane will host a listen-only webcast conference call at 11:00 a.m. ET on August 4, with a replay accessible for one year on the same site.
Hamilton Lane (Nasdaq: HLNE) announced the final close of its sixth Direct Equity vehicle, Hamilton Lane Equity Opportunities Fund VI (EO VI), with $3.8 billion in total commitments in and alongside the fund, up from $2.1 billion for Fund V.
EO VI targets diversified middle-market buyout opportunities through Hamilton Lane's global Direct Equity platform, which has $22.2 billion AUM*, a 43-person team and more than 30 years of activity. Over the past two years, the Direct Equity platform generated $6 billion in distributions and has completed 787 discretionary direct equity investments since inception.
Gridline announced a strategic technology integration with Hamilton Lane (Nasdaq: HLNE), adding Hamilton Lane’s proprietary private markets benchmarking data to Gridline’s AI-powered diligence platform AltComply.
The integration lets RIAs, multi-family offices and private banks benchmark managers by peer group and vintage year and, according to Gridline, save an average of 10 hours per fund evaluated.
Hamilton Lane (Nasdaq: HLNE) reported fourth quarter and fiscal year 2026 results for the period ended March 31, 2026 and posted a detailed presentation on its shareholders website.
The company declared a higher dividend, expanded its stock repurchase authorization to $100 million and reported $1 trillion in assets under management and supervision.
Cosette Pharmaceuticals (HLNE) appointed David Bell as Chief Commercial Officer (Brands), joining the executive leadership team.
He will oversee all branded commercial functions, drive performance across 21 marketed brands, support integration of acquired assets, and align commercial execution with Cosette’s strategic and financial objectives.
MidOcean Partners closed a single-asset continuation vehicle for Cloyes (automotive timing-drive systems), securing approximately $300 million in commitments with Hamilton Lane (Nasdaq: HLNE) as sole lead investor. MidOcean made an additional investment and will retain a controlling stake; CEO John Hanighen was named Chairman.
The transaction funds Cloyes’ growth plans, supports acquisitions, and gives existing investors optional liquidity while extending MidOcean’s partnership with the company.
Cosette Pharmaceuticals (NASDAQ:HLNE) appointed Erika Tooman as Senior Vice President, General Counsel effective April 29, 2026. Tooman will oversee legal, compliance, governance, and risk management as Cosette scales its platform following recent acquisitions and continued growth initiatives. She joins from Radius Health and holds a JD, an MS in Biotechnology, and a BA in Biology.
The hire is presented as support for the company’s business development, M&A integration, and governance as Cosette pursues portfolio expansion and strategic partnerships.